(Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission File No. 001-36483 MIRAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ...

Cobomarsen (miR-155 inhibitor) in Hematological Malignancies - Cobomarsen achieved human Phase 1 clinical proof-of-concept in Cutaneous T-Cell Lymphoma (CTCL)[6] - A controlled Phase 2 clinical trial in CTCL was recently initiated, with data potentially allowing for accelerated approval[6] - Promising clinical results were obtained in the treatment of Adult T-cell Leukemia/Lymphoma (ATLL)[6] - In a Phase 1 trial, 92% of MF subjects in the systemic administration cohorts showed improvement in tumor burden as assessed by mSWAT score[21] - 63% of subjects treated with cobomarsen at a 300 mg IV-infusion achieved a partial response (PR)[21,26] - The estimated potential worldwide market opportunity for Cobomarsen in CTCL is over $1 billion[18] Remlarsen (miR-29 replacement) in Pathological Fibrosis - Mechanistic proof-of-concept in dermal scarring was obtained from a Phase 1 clinical trial[6] - A Phase 2 clinical trial in pathological cutaneous fibrosis is expected to have a readout in the second half of 2019[6] - Blinded histology analysis showed a statistically significant (p=00086) reduction of fibroplasia in a human Phase 1 clinical trial[56,58] MRG-110 (miR-92 inhibitor) in Cardiovascular Disease - Two Phase 1 clinical trials for systemic and local administration are expected to have readouts in 2019[6] - Development is funded by Servier, with miRagen retaining commercial rights in the United States and Japan[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K ____________________________________________ Washington, D.C. 20549 ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 _____________________________________ ...

miRagen Therapeutics, Inc. (MGEN) Q4 2018 Earnings Conference Call March 13, 2019 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors, LLC William Marshall - Co-Founder, President and Chief Executive Officer Jason Leverone - Chief Financial Officer Paul Rubin - Executive Vice President of Research and Development Adam Levy - Chief Business Officer Conference Call Participants Jonathan Miller - Evercore ISI Suji Jeong - Jefferies LLC Vasiliana Moussatos - Wedbush Securities Inc. Madhu Kumar - Rob ...